Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer


Alexander Sulakvelidze

Alexander Sulakvelidze

Chief Scientist
Intralytix Inc.


Dr. Alexander “Sandro” Sulakvelidze, Ph.D., is a Chief Scientist and Vice-President for Research & Development of Intralytix, Inc. Dr. Sulakvelidze is an internationally recognized expert in phage technology and infectious disease epidemiology. He has served/is serving as the Principal Investigator/Project Director of several grants and contracts from various agencies and foundations, including the National Institutes of Health (NIH), United States Department of Defense (DOD), United States Environmental Protection Agency (EPA), United States Department of Agriculture (USDA), National Food Processors Association (NFPA), Department of Health and Human Services Biotechnology Engagement Program (BTEP), and the Civilian Research and Development Foundation (CRDF). Dr. Sulakvelidze has published extensively on the subjects of molecular epidemiology and phage therapy, and he is the author of several issued and pending patents in the field of bacteriophages. He also co-edited a major book about bacteriophages, which was published by the CRC Press in 2005. Dr. Sulakvelidze serves as Editor-in-Chief of the journal Bacteriophage. His research has been featured in several magazines and newspapers (including the Los Angeles Times, Newsweek, Science, Smithsonian, Wired, and Discover Magazine), and in various radio programs and television documentaries (including National Public Radio’s Science Friday, BBC Radio and Voice of America radio programs, and BBC Horizon documentary about phage therapy). Dr. Sulakvelidze serves as an ad hoc reviewer for various journals, such as Antimicrobial Agents and Chemotherapy, Applied and Environmental Microbiology, Drug Discovery Today, FEMS Immunology and Medical Microbiology, FEMS Microbiology Letters, Clinical and Experimental Dermatology, Food Microbiology, Trends in Biotechnology, Journal of Clinical Microbiology, and Therapeutic Delivery, and for several funding agencies, including the CRDF, the International Science and Technology Center (ISTC), the Qatar Research Fund, the U.S.-Israel Binational Science Foundation (BSF), and the NIH.

Research Interest